Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Autologous Stem Cell Transplantation for Multiple Myeloma Patients Whose Myeloma Defining Event Was Slim

Iuliana Vaxman, Shaji Kumar, Inbar Cohen, Shai O. Shimony, Angela Dispenzieri, Francis Buadi, David Dingli, Martha Lacy, Eli Muchtar, Prashant Kapoor, William J. Hogan, Suzanne R Hayman, Nelson Leung, Wilson I. Gonsalves, Taxiarchis Kourelis, Rahma M Warsame, Morie A. Gertz

Blood (2024) 144 (Supplement 1): 7078.

https://doi.org/10.1182/blood-2024-205062

Published: 2024

Journal Articles

Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial

Blood (2024) 144 (Supplement 1): 6965.

https://doi.org/10.1182/blood-2024-202392

Published: 2024

Journal Articles

A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1985.

https://doi.org/10.1182/blood-2024-206912

Published: 2024

Journal Articles

Towards a Decision Engine for Therapeutic Optimization of Relapsed Refractory Multiple Myeloma

Yael C. Cohen, Mor Zada, Shuang-Yin Wang, Assaf Weiner, Natan Melamed, Polina Stepensky, Moshe E Gatt, Shlomit Kfir-Erenfeld, Nathalie Asherie, Eyal Lebel, Irit Avivi Mazza, Anna Gurevich Shapiro, Iuliana Vaxman, Tamir Shragai, Paulina Chalan, Eyal David, Ido Amit

Blood (2023) 142 (Supplement 1): 341.

https://doi.org/10.1182/blood-2023-190178

Published: 2023

Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Yael C. Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Moshe Mittelman, Inna Tzoran, Vladimir Vainstein, Noa Lowenton-Spier, Natan Melamed, Ella Krayzler, Ilana Pereg, Irit Avivi Mazza

Blood (2023) 142 (Supplement 1): 2014.

https://doi.org/10.1182/blood-2023-185830

Published: 2023

Journal Articles

Smoldering Multiple Myeloma Progressing to Active Multiple Myeloma Vs De-Novo Active Multiple Myeloma - a Comparison of Disease Characteristics, Organ Involvement and Outcomes in a Real-Life Multicenter Retrospective Cohort Study

Yael C. Cohen, Gil Fridberg, Inbar Cohen, Renana Robinson, Iuliana Vaxman, Tamir Shragai, Svetlana Trestman, Tomer Ziv-Baran, Natan Melamed, Pia Raanani, Irit Avivi Mazza

Blood (2023) 142 (Supplement 1): 4728.

https://doi.org/10.1182/blood-2023-186140

Published: 2023

Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Yael C Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Noa Lowenton-Spier, Liron Gez-Aaronson, Natan Melamed, Irit Avivi

Blood (2022) 140 (Supplement 1): 10131–10132.

https://doi.org/10.1182/blood-2022-164722

Published: 2022

Journal Articles

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Blood (2022) 140 (Supplement 1): 4426–4427.

https://doi.org/10.1182/blood-2022-164572

Published: 2022

Journal Articles

High Implementation Adherence to Lenalidomide in Patients with Multiple Myeloma

Avi Leader, Hila Magen, Irina Amitai, Antoine Pironet, Eric Tousset, Alon Rozental, Sabina De Geest, Iuliana Vaxman, Pia Raanani, Arnon Nagler

Blood (2022) 140 (Supplement 1): 8068–8069.

https://doi.org/10.1182/blood-2022-163818

Published: 2022

Journal Articles

"Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia - a Multi-Center Retrospective Study

Gilad Itchaki, Ohad Benjamini, Mor Levi, Anatoly Nemets, Shay Yeganeh, Mahdi Assaly, Anna Gourevitch, Revital Saban, Moshe E Gatt, Pia Raanani, Iuliana Vaxman

Blood (2022) 140 (Supplement 1): 11981–11982.

https://doi.org/10.1182/blood-2022-163009

Published: 2022

Journal Articles

How I approach smoldering multiple myeloma

Iuliana Vaxman, Morie A. Gertz

Blood (2022) 140 (8): 828–838.

https://doi.org/10.1182/blood.2021011670

Published: 2022

Journal Articles

"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience

Blood (2021) 138 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2021-147925

Published: 2021

Journal Articles

Between a Rock and a Hard Place: Paraproteinemia Associated with Chronic Myeloid Leukemia

Tamar Berger, Adi Shacham Abulafia, Shai Shimony, Oren Pasvolsky, Iuliana Vaxman, Yifat Miron, Shimrit Feldman, Avi Leader, Pia Raanani

Blood (2021) 138 (Supplement 1): 1488.

https://doi.org/10.1182/blood-2021-149206

Published: 2021

Journal Articles

Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review

Iuliana Vaxman, MD, Alissa Visram, MD, Oren Pasvolsky, MD, Shaji K. Kumar, MD, Angela Dispenzieri, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Martha Q. Lacy, MD, Suzanne R. Hayman, MD, Robert A. Kyle, MD, Prashant Kapoor, MD, Nelson Leung, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, Rahma M Warsame, MD, Abdullah S. Al Saleh, Morie A. Gertz, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-138640

Published: 2020

Journal Articles

Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation

Abdullah S. Al Saleh, MBBS, Iuliana Vaxman, MDBA, Harsh Parmar, MD, Alissa Visram, MD, M Hasib Sidiqi, MBBS, Eli Muchtar, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Martha Q. Lacy, MD, Rahma M Warsame, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, William J Hogan, MB, BCh, Prashant Kapoor, MD, Robert Wolf, PharmD, RPh, Angela Dispenzieri, MD, Shaji K. Kumar, MD, Morie A. Gertz, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-143076

Published: 2020

Journal Articles

A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139670

Published: 2020

Journal Articles

Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents

Iuliana Vaxman, MD, Alissa Visram, MD, Shaji K. Kumar, MD, Angela Dispenzieri, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Martha Q. Lacy, MD, Eli Muchtar, MD, Prashant Kapoor, MD, William J Hogan, MB, BCh, Suzanne R. Hayman, MD, Nelson Leung, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, Rahma M Warsame, MD, Tamar Berger, MD, Morie A. Gertz, MD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-138625

Published: 2020

Journal Articles

Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis

Abdullah S. Al Saleh, MBBS, Iuliana Vaxman, MDBA, Harsh Parmar, MD, M Hasib Sidiqi, MBBS, Eli Muchtar, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Martha Q. Lacy, MD, Rahma M Warsame, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, William J Hogan, MB, BCh, Prashant Kapoor, MD, Robert Wolf, PharmD, RPh, Angela Dispenzieri, MD, Shaji K. Kumar, MD, Morie A. Gertz, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-143125

Published: 2020

Journal Articles

Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation

Iuliana Vaxman, MDBA, Alissa Visram, MD, Prashant Kapoor, MD, Abdullah S. Al Saleh, Shaji K. Kumar, MD, Angela Dispenzieri, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Eli Muchtar, MD, Wilson I Gonsalves, MD, S. Vincent Rajkumar, MD, Taxiarchis Kourelis, MD, Rahma M Warsame, MD, Martha Q. Lacy, MD, Morie A. Gertz, MD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-141660

Published: 2020

Journal Articles

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Svetlana Trestman, MD, Chezi Ganzel, MD, Shai Levi, MSc, Moshe E. Gatt, MD, Noa Lavi, MD, Iuliana Vaxman, MDBA, Ory Rouvio, MD, Hila Magen, MD, Netanel A Horowitz, MD, Merav Leiba, MD, Tamar Tadmor, MD, Katrin Herzog Tzarfati, MD, Celia Surio, MD, Shay Yeganeh, MD, Nagib Deli, MD, Irit Avivi, MD, Cohen Yael, Dr.

Blood (2019) 134 (Supplement_1): 3180.

https://doi.org/10.1182/blood-2019-128325

Published: 2019

NARROW

Autologous Stem Cell Transplantation for Multiple Myeloma Patients Whose Myeloma Defining Event Was Slim

Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial

A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Towards a Decision Engine for Therapeutic Optimization of Relapsed Refractory Multiple Myeloma

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Smoldering Multiple Myeloma Progressing to Active Multiple Myeloma Vs De-Novo Active Multiple Myeloma - a Comparison of Disease Characteristics, Organ Involvement and Outcomes in a Real-Life Multicenter Retrospective Cohort Study

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

High Implementation Adherence to Lenalidomide in Patients with Multiple Myeloma

"Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia - a Multi-Center Retrospective Study

How I approach smoldering multiple myeloma

"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience

Between a Rock and a Hard Place: Paraproteinemia Associated with Chronic Myeloid Leukemia

Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review

Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation

A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial

Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents

Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis

Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only